Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
Liminatus Pharma, Inc. (NASDAQ: LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment... - October 27, 2025
Liminatus Pharma Announces Receipt of Nasdaq Listing Delinquency Letter
Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies, today announced that on August 22, 2025, it received a notification letter from Nasdaq indicating that... - August 26, 2025
Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101
Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy. Since its Nasdaq debut earlier this year, Liminatus Pharma has been preparing to redefine the immune-oncology landscape with IBA101, a novel CD47 checkpoint... - June 24, 2025
Liminatus Pharma Announces Compliance with Nasdaq Filing Requirements
Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies, today announced that on June 3, 2025, it received a notification letter from Nasdaq indicating that it... - June 04, 2025